---
title: "Weekly Recap | INNOCARE -4.21%, two pipeline milestones hit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305539972.md"
description: "InnoCare fell 4.21% this week to close at HK$11.61, underperforming the Hang Seng Index by about 0.89 percentage points. The stock opened higher on Monday, then drifted lower through the week, touching a weekly low of HK$11.54 on Thursday before a small bounce. The weekly range was 6.58%, with average daily volume about 60% of its historical median, indicating lighter-than-usual trading."
datetime: "2026-11-14T07:28:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305539972.md)
  - [en](https://longbridge.com/en/news/305539972.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305539972.md)
generator: "portal-rs"
---

# Weekly Recap | INNOCARE -4.21%, two pipeline milestones hit

## The Week

InnoCare fell 4.21% this week to close at HK$11.61, underperforming the Hang Seng Index by about 0.89 percentage points. The stock opened higher on Monday, then drifted lower through the week, touching a weekly low of HK$11.54 on Thursday before a small bounce. The weekly range was 6.58%, with average daily volume about 60% of its historical median, indicating lighter-than-usual trading.

## Key Events

This was a busy week for clinical updates. On Monday, InnoCare dosed its first patient in a Phase III trial of mesutoclax versus venetoclax in acute myeloid leukaemia, a key registrational study in haematologic oncology. On Wednesday, the company dosed its first patient in a Phase I trial of ICP-B381, a cancer drug, in China. These two pipeline milestones form the core narrative of the week.

## Analyst Ratings

The latest consensus shows 11 covering institutions: 9 rate it buy and 2 rate it over, with no hold, under, or sell ratings. The consensus recommendation is strong buy, with a consensus target of HK$18.13, about 56.2% above the current price. Individual targets range from HK$8.922 to HK$23.131, a wide spread. InnoCare ranks 8th among 52 companies in the biotech industry.

## The Week Ahead

Hong Kong macro data dominates next week. The unemployment rate is due Tuesday, with a prior reading of 3.9, and the composite CPI is due Friday, with a previous print of 1.9. On the corporate side, the next scheduled earnings release is the FY2026 annual report on 25 March 2027, with estimated EPS of 0.3889 and revenue of HK$3.147 billion.

## In Short

Clinical momentum picked up this week, with two investigational drugs reaching first-patient dosing, and the analyst consensus remains strong buy with a target well above spot. Yet the stock lost more than 4% over the week, and the latest trading day showed medium and small-lot flows dominating while large-lot money stayed roughly flat. That gap between news flow and price action is the tension to watch. Next, Hong Kong macro data will set the near-term tone for risk appetite, alongside further updates from the company’s pipeline.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization](https://longbridge.com/en/news/303068907.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**